Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
However, it still needs to be used appropriately, especially if a person has symptoms or a confirmed deficiency
International shipping is not currently offered
Post-Market Surveillance Gap: Because AOD-9604 never received FDA approval for any indication, there is no post-market surveillance system capturing safety signals from widespread clinical use
Follow all directions on your prescription label and read all medication guides or instruction sheets
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Lot Traceability and Public COA Library Each vial carries a unique lot number printed on the label that maps to the complete analytical record for that batch, including HPLC, LC-MS, disulfide bond verification, and endotoxin readings
